Caricamento...
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and CDK4/6 inhibitors are FDA-approved for treating patients with metastatic breast cancer. However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive. Here, we report i...
Salvato in:
| Pubblicato in: | Angew Chem Int Ed Engl |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678623/ https://ncbi.nlm.nih.gov/pubmed/30802347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201901336 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|